Research analysts at Guggenheim started coverage on shares of Medidata Solutions (NASDAQ:MDSO) in a note issued to investors on Wednesday, April 17th, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $92.00 price target on the stock. Guggenheim’s price target suggests a potential downside of 0.88% from the company’s previous close.
Several other brokerages have also issued reports on MDSO. Leerink Swann started coverage on Medidata Solutions in a research note on Wednesday, January 2nd. They set a “market perform” rating and a $70.00 price target on the stock. Zacks Investment Research lowered Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Piper Jaffray Companies lowered their price target on Medidata Solutions to $83.00 and set an “overweight” rating on the stock in a research note on Friday, January 4th. TheStreet lowered Medidata Solutions from a “b” rating to a “c+” rating in a research note on Thursday, December 20th. Finally, William Blair started coverage on Medidata Solutions in a research note on Monday, April 15th. They set an “outperform” rating and a $74.93 price target on the stock. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Medidata Solutions currently has a consensus rating of “Hold” and a consensus target price of $84.60.
NASDAQ MDSO opened at $92.82 on Wednesday. Medidata Solutions has a twelve month low of $60.10 and a twelve month high of $98.60. The company has a quick ratio of 2.71, a current ratio of 2.57 and a debt-to-equity ratio of 0.14. The stock has a market cap of $5.73 billion, a P/E ratio of 96.69, a price-to-earnings-growth ratio of 8.52 and a beta of 1.42.
In other news, EVP Daniel Patrick Shannon sold 19,725 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $75.17, for a total value of $1,482,728.25. Following the sale, the executive vice president now directly owns 70,497 shares in the company, valued at approximately $5,299,259.49. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael Pray sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $76.50, for a total value of $1,147,500.00. Following the completion of the sale, the executive vice president now owns 77,134 shares in the company, valued at $5,900,751. The disclosure for this sale can be found here. Corporate insiders own 4.70% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC grew its position in Medidata Solutions by 126.8% during the 1st quarter. Quadrant Capital Group LLC now owns 592 shares of the company’s stock worth $40,000 after acquiring an additional 331 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its position in Medidata Solutions by 127.2% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 945 shares of the company’s stock worth $64,000 after acquiring an additional 529 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its position in Medidata Solutions by 26.9% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,286 shares of the company’s stock worth $87,000 after acquiring an additional 273 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new stake in Medidata Solutions during the 4th quarter worth approximately $90,000. Finally, Canton Hathaway LLC bought a new stake in Medidata Solutions during the 1st quarter worth approximately $109,000.
About Medidata Solutions
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
See Also: Why is total return important?
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.